Page last updated: 2024-12-06
benzydamine n-oxide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
benzydamine N-oxide: RN given refers to parent cpd; structure given in first source; metabolite of benzydamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 65465 |
MeSH ID | M0140368 |
Synonyms (11)
Synonym |
---|
benzydamine n-oxide |
3-(1-benzylindazol-3-yl)oxy-n,n-dimethylpropan-1-amine oxide |
FT-0662622 |
FT-0662623 |
1-propanamine, n,n-dimethyl-3-((1-(phenylmethyl)-1h-indazol-3-yl)oxy)-, n-oxide |
36504-71-9 |
DTXSID90190005 |
AKOS030242013 |
3-((1-benzyl-1h-indazol-3-yl)oxy)-n,n-dimethylpropan-1-amine oxide |
CS-0646597 |
HY-N11425 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" Simulations of human plasma concentrations of benzydamine and its N-oxide were achieved using simplified physiologically based pharmacokinetic models based on data from control TK-NOG mice and from reported benzydamine concentrations after low-dose administration in humans." | ( Human plasma metabolic profiles of benzydamine, a flavin-containing monooxygenase probe substrate, simulated with pharmacokinetic data from control and humanized-liver mice. Mitsui, M; Nishiwaki, M; Shimizu, M; Suemizu, H; Yamazaki, H; Yamazaki-Nishioka, M, 2018) | 0.48 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" In addition, the confirmed low bioavailability of the drugs excludes the possibility of any accumulation effects and limits the risk of undesired systemic effects." | ( Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and Benzydamine. Bovi, G; Caccia, G; Comandini, A; Di Stefano, AFD; Focanti, F; Olivieri, S; Pelacchi, F; Picollo, R; Radicioni, MM; Rosignoli, MT; Salvatori, E; Vaccani, A, 2020) | 0.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.76) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (12.50%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |